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Objective.-To develop and validate an approach that uses clinical features that 
can be determined in a standard patient visit to estimate the length of time before 
an individual patient with Alzheimer disease (AD) requires care equivalent to nurs-
ing home placement or dies. 
Design.-Prospective cohort study of 236 patients, followed up semiannually for 
up to 7 years. A second validation cohort of 105 patients was also followed. 
Setting.-Three AD research centers. 
Patients.-All patients met National Institute of Neurological and Communica-
tive Disorders and Stroke-Alzheimer's Disease and Related Disorders Association 
(NINCDS-ADRDA) criteria for probable AD and had mild dementia at the initial visit. 
lntervention.-Predictive features, ascertained at the initial visit, were sex, du-
ration of illness, age at onset, modified Mini-Mental State Examination (mMMS) 
score, and the presence or absence of extrapyramidal signs or psychotic features. 
Main Outcome Measures.-(1) Requiring the equivalent of nursing home 
placement and (2) death. 
Results.-Prediction algorithms were constructed for the 2 outcomes based on 
Cox proportional hazard models. For each algorithm, a predictor index is calculated 
based on the status of each predictive feature at the initial visit. A table that speci-
fies the number of months in which 25%, 50%, and 75% of patients with any spe-
cific predictor index value are likely to reach the end point is then consulted.Survival 
curves for time to need for care equivalent to nursing home placement and for time 
to death derived from the algorithms for selected predictor indexes fell within the 
95% confidence bands of actual survival curves for patients.When the predictor 
variables from the initial visit for the validation cohort patients were entered into the 
algorithm, the predicted survival curves for time to death fell within the 95% con-
fidence bands of actual survival curves for the patients. 
Conclusions.-The prediction algorithms are a first but promising step toward 
providing specific prognoses to patients, families, and practitioners. This approach 
also has clear implications for the design and interpretation of clinical trials in pa-
tients with AD. 
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DE SPITE numerous advances in the bio-
logical study of Alzheimer disease (AD), 
we remain unable to reliably estimate 
the length of time from disease onset to 
important disease end points such as nurs-
ing home admission or death. Patients 
with AD and their families typically may 
inquire when to expect these end points, 
but it has not been possible provide an 
accurate, empirically based answer. The 
presence of extrapyramidal signs or psy-
chosis and younger age at disease onset 
are associated with more rapid disease 
course.1-6 This article presents the devel-
opment and validation of an approach that 
uses these clinical features to estimate 
the length of time before a patient re-
quires nursing home care or dies. These 
algorithms represent the first attempt 
we know of to make such predictions for 
individual patients. 
METHODS 
Subjects were members of the Pre-
dictors Study cohort.7 A total of 236 pa-
tients with probable AD were recruited 
at 3 sites: Columbia University College 
of Physicians and Surgeons, New York, 
NY; Johns Hopkins University School of 
Medicine, Baltimore, Md; and Massachu-
setts General Hospital, Boston. Inclusion 
and exclusion criteria, recruitment meth-
ods, and the full evaluation battery have 
been described. 7 Each patient met Na-
tional Institute ofN eurological and Com-
municative Disorders and Stroke-Alzhei-
mer's Disease and Related Disorders 
Association (NIN CDS-AD RDA) criteria 
for probable AD,8 with 1 exception de-
scribed below. To ensure that severity of 
dementia was mild at study entry, 
all patients were required to have a modi-
fied Mini-Mental State Examination 
(mMMS) score of 30 or above (corres-
ponding to approximately lEi on the stan-
dard Mini-Mental State Examination 
[MMSE]). To ensure accurate initial as-
sessment of psychotic symptoms, all pa-
tients were required to not be treated 
with neuroleptic medications for at least 
1 month prior to their initial evaluation. 
Exclusion criteria were history or cur-
rent clinical evidence of substance abuse, 
schizophrenia, schizoaffective disorder, or 
major affective disorder prior to the on-
set of intellectual decline; any electrocon-
vulsive therapy treatment within 2 years 
of recruitment, or 10 or more electrocon-
vulsive treatments at any time; history 
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or clinical signs of stroke or a Hachinski 
Ischemic Score9 of 5 or more. Patients 
with small subcortical lesions on computed 
tomographic or magnetic resonance im-
aging scans that were clinically and his-
torically silent and were judged to be less 
than 2 cm in diameter were included, as 
were those with diffuse symmetric peri-
ventricular lucencies. However, patients 
with cortical lesions of any size or loca-
tion or with focal cortical atrophy in a 
specific vascular distribution were ex-
cluded. 
This project was approved by the in-
stitutional review board at each partici-
pating institution, and all patients pro-
vided written informed consent. 
Procedures 
Predictors.-At the initial visit, the fol-
lowing predictive features were assessed: 
Duration of Illness.-The clinician es-
timated disease duration based on in-
terviews with the patient and infor-
mants. As part of the standard medical 
history, the clinician asked the infor-
mants to date the onset of clinical fea-
tures such as memory, performance, and 
language changes in order to date the 
onset of the disease. Clinicians' estimates 
were separately confirmed using a stan-
dardized interview technique. 10 
Age at Onset.-Based on this inter-
view, age at onset of dementia was char-
acterized as young (younger than 65 
years) or old (age 65 years or older). 
Extrapyramidal Signs.-Selected 
items from the Unified Parkinson's Dis-
ease Rating Scale (UPDRS)11 were used 
to rate extrapyramidal signs. Hypopho-
nia, masked faces, resting tremor, ri-
gidity (neck and each limb), brady/ 
hypokinesia, and posture and gait 
abnormalities were rated as absent, 
slight, mild to moderate, marked, or se-
vere.12 Patients who had at least 1 sign 
rated as mild to moderate were consid-
ered to have extrapyramidal signs since 
ratings of this severity are more reliable 
and are apt to be noted by the average 
clinician.12 Our analyses focused on non-
drug-induced extrapyramidal signs. If a 
patient's signs were possibly or prob-
ably drug-induced, then they were not 
considered extrapyramidal signs for the 
purpose of prediction and were not in-
cluded in the statistical analyses. 
Psychosis.-A semistructured inter-
view, the Columbia University Scale for 
Psychopathology in Alzheimer's Disease 
(CUSPAD),13 was used to elicit infor-
mation about delusions, hallucinations, 
and other specific behavioral signs oc-
curring tluring the month prior to as-
sessment. Specific delusions queried in-
cluded paranoid delusions, delusions of 
abandonment, somatic delusions, and mis-
identifications. We used the presence of 
JAMA, March 12, 1997-Vol 277, No. 10 
delusions or hallucinations at the initial 
visit as evidence of psychosis. 
Cognition.-Cognitive function was 
examined using the mMMS,14·15 which 
includes the items from the standard 
MMSE,16 the Wechsler Adult Intelli-
gence Scale-Revised (WAISR) Digit 
Span subtest, 17 and additional attention/ 
calculation, general knowledge, lan-
guage, and construction items. The maxi-
mum score on the mMMS is 57. 
Other measures were also obtained at 
each study visit, including the Blessed 
Dementia Rating Scale (BDRS) (Part 1)18 
to assess functional capacity, and the Clini-
cal Dementia Rating(CDR) Scale19 to rate 
the overall severity of the dementia. 
Outcomes.-Patients were followed 
up semiannually for up to 7 years. The 
following 2 outcomes were considered. 
Health-Related Facility Care.-The 
"equivalent institutional care"20 that the 
patient was receiving was rated at each 
6-month follow-up interval. This rating 
summarizes the interviewer's impres-
sion, based on data from the entire study 
protocol,7 of the care the patient received 
and required, regardless of the patient's 
location. Categories are limited home 
care; adult home (a supervised setting 
with regular assistance in most activi-
ties); and health-related facility (nurs-
ing home care). We used the rating 
equivalent to care in a health facility as 
an end point for prediction since it is 
equivalent to nursing home plac:ement, 
an important event for families of pa-
tients with AD. Interrater reliability for 
the equivalent care rating is good; the 
intraclass correlation coefficient was 0. 73 
in a study of 20 patients.20 
Death.-Autopsies were obtained 
whenever possible. When autopsies were 
not obtained, we typically learned of pa-
tients' deaths from family members or 
when attempting to complete follow-up 
visits. For patients who could not be 
contacted for follow-up or were other-
wise unavailable for follow-up, death in-
formation was obtained as available 
through the National Death Index. 
Validation Population.-A popula-
tion was selected in which to assess the 
accuracy of the algorithm with respect 
to the death outcome. We used data from 
elders with dementia in North Manhat-
tan who are being followed up prospec-
tively as part of another epidemiologic 
study.None of these patients were mem-
bers of the Predictors Study cohort. 
These patients also met NINCDS-
ADRDA criteria for probable AD based 
on neurological examination, neuropsy-
chological testing, and functional evalu-
ation. Duration of illness, extrapyrami-
dal signs, and mortality information were 
collected as described above. The mMMS 
was not administered to this population, 
so we developed a regression equation 
to estimate mMMS scores on the basis 
of 2 tests they did receive, the short 
Blessed test21 and total recall on the 
Selective Reminding Test.22 The equa-
tion was based on a group of 255 prob-
able AD patients who took all 3 tests. 
The multiple R for the regression equa-
tion was 0.72. Patients were included in 
the validation analysis if the UPDRS, 
duration of illness estimates, and data 
required to estimate the mMMS score 
were available and if the estimated 
mMMS was at least 2fi. This provided 
105 patients for the current analyses. 
Apolipoprotein E.-Apolipoprotein E 
(APO E) studies were not an original com-
ponent of this study. However, we wanted 
to determine whether A.POE genotype 
influenced the prediction algorithms that 
we developed. Beginning in the sixth year 
of the study, available subjects were ap-
proached to contribute blood samples for 
analysis. In addition, analyses were con-
ducted on frozen brain tissue of 12 pa-
tients who had died and contributed their 
brains for postmortem studies. 
The pattern of each subject's APOE 
isoforms was determined using the 
method of Hixson and Vernier.23 The 
white blood cells were isolated from fresh 
blood samples after centrifugation at 2000 
rpm for 20 minutes at 4°C, and the DNA 
was digested with HhAI. Leukocyte DNA 
was amplified by polymerase chain reac-
tion (PCR) using specifically synthesized 
oligonucleotide primers and Taq polymer-
ase. The amplified APOE products were 
then digested with 5 units of HaAl en-
zyme at 37°C for 4 hours. The digest was 
electrophoresed on a 12% nondenaturing 
polyacrylamide gel for 3 hours at a con-
stant current of 10 mA. The gels were 
then treated with ethidium bromide for 
10 to 15 minutes, and the DNA fragments 
were visualized by ultraviolet illumina-
tion. Fragments of DNA of knovm size 
were used as markers. 
Data Analyses 
Cox Analysis.-Cox proportional haz-
ard analyses used the predictors listed 
above: extra pyramidal signs, psychosis, 
and age at onset. Initial mMMS score, 
estimated duration of illness, and sex 
were also considered as potential covar-
iates. Since older patients might reach 
the defined end points sooner, all Cox 
analyses were stratified by the median 
age at first visit, 73 years. 
Reaching the equivalent of nursing 
home care and death were the 2 outcomes 
considered. For each outcome, we calcu-
lated a Cox proportional hazards model 
that used months from the initial visit as 
the timing variable. After calculating each 
model, it was "trimmed back" to include 
only those covariates th.at were associ-
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Table 1.-Cox Proportional Hazard Analysis 
Pred icting Reach ing an Institutional Care Rating 
Equivalent to Health-Related Facility Care* 
Predictor p RR (95% Cl) 
EPS present 0.9419 2.56 (1.49-4.41) 
Psychotic symptoms 
present 0.4027 1.50 (1.04-2.15) 
Young age at onset, 
< 65 y 0.4848 1.62 (0.99-2.67) 
mMMS score 
(each unit) - 0.0724 0.93 (0.90-0.96) 
Duration of illness, y - 0.0617 0.94 (0.87-1.01) 
*RR indicates relative risk; Cl , confidence interval; 
EPS, extrapyramidal signs; and mMMS, modified Mini-
Mental State Examination . 
ated with significant or borderline (P<.10) 
significant increases in relative risk. We 
used the martingale methods to check 
the proportional hazards assumption.24 
Derivation of the Predictor Algo-
rithms.-Predictor algorithms for nurs-
ing home care and mortality endpoints 
were then developed, based on the Cox 
models. Using a Cox model, a survival 
curve for any individual patient can be 
estimated based on the value of that 
patient's covariates. 
The algorithm has 2 steps. First, a 
patient's predictor index is calculated. 
In Cox models, the risk associated with 
a given set of covariates can be specified 
by summing the products of the covar-
iates and their associated [3 weights. 
Second, a table that specifies the num-
ber of months in which a patient with a 
specific predictor index value is likely to 
reach the end point of interest is con-
sulted. To construct the table, we calcu-
lated the predictor index for each patient 
in the cohort and then estimated the sur-
vival curve for a representative range of 
values. Based on these curves we deter-
mined and entered into the table the num-
ber of months in which 25%, 50%, and 
75% of patients with a specific index value 
would be expected to reach an endpoint. 
Since the Cox analyses were stratified at 
age 73 years, separate tables were con-
structed for the young and old age groups. 
Validation of the Predictor Algo-
rithms.-We compared the algorithm-
derived survival curve for a specific pre-
dictor index value to a survival curve 
describing patients who had similar pre-
dictor indexes at their initial visit. We 
posited that if these curves are similar, 
then the predictions based on the index 
would closely match the actual survival 
distribution of patients with that index. 
To compare these 2 curves, we calcu-
lated the 95% confidence band around 
the survival curve for actual patient data 
and then determined whether the curve 
derived from the prediction algorithm 
was contained within this band. 
The initial validation was performed in 
the same cohort used to derive the algo-
rithm to test how well the derived Cox 
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Table 2.-Guide for Calculating a Patient's Predictor Index for Health-Related Facility Care* 
Predictor Coding Value Weight Value x Weight 
EPS 0 Absent, 1 present x - 0.9419 
Psychotic symptoms 0 Absent, 1 present x - 0.4027 
Age at onset 0 Normal, 1 young (< 65 y) x - 0.4848 
mMMS Actual score x 0.0724 
Duration of illness Estimated years x 0.0617 
HRF care predictor index (sum) 
*Using the coding guidelines, a value for each predictor is entered into the "Value" column. The product of each 
predictor's value and weight is entered in the far right column. The predictor index is the sum of these products. Using 
this predictor index, estimates of the time until health-related facility (HRF) care will be required can be looked up 
in Table 3. EPS indicates extrapyramidal signs ; and mMMS, modified Mini-Mental State Examination. 
Table 3.-Specific Prediction of Months Until a Patient Will Require Health-Related Facility Care, Based on 
Predictor Index* 
Young (s;73 y) Old (> 73 y) 
HRF Care 
index 25% 50% 75% 25% 50% 75% 
1.0 12.2 16.9 24.6 8.9 13.3 18.8 
1.2 13.1 18.9 29.1 11 .1 15.7 . 19.5 
1.4 13.1 21.2 30.3 11.5 16.8 23.6 
1.6 14.9 24.3 36.0 12.0 18.4 24.1 
1.8 16.8 25.9 37.6 12.7 18.9 28.3 
2.0 18.3 29.7 42.6 13.4 22.9 30.3 
2.2 20.2 34.0 27.8 16.3 23.7 37.7 
2.4 22.7 36.8 53.0 17.9 24.7 42.7 
2.6 24.7 41.4 54.9 18.9 28.8 47.2 
2.8 29.2 43.9 59.4 20.7 34.1 61.4 
3.0 31.1 49.9 60.7 23.6 38.1 66.6 
3.2 36.3 53.5 60.7 24.5 44.4 
3.4 38.2 58.6 28.8 48.6 
3.6 42.6 60.7 30.4 66.2 
3.8 47.8 67.1 38.0 
4.0 53.0 44.3 
4.2 54.9 47.6 
4.4 59.4 61.4 
*For each predictor index value (as calculated in Table 2) , the table shows number of months within which the 
specified percentage of comparable patients require the equivalent of health-related facility (HRF) care. Values for 
younger (s;73 years) and older (> 73 years) patients are provided separately. Empty cells represent patients with 
milder severity at their initial visit (and thus higher predictor index values) for whom there are insufficient data to 
generate predictions. 
models and their implementation in the 
predictor algorithm fit the actual patient 
data. To do this, we calculated Kaplan-
Meier curves and 95% confidence bands 
for patients whose predictor indexes were 
within a 1-unit range. These curves were 
compared with those generated by the 
algorithm for a predictor index in the cen-
ter of that range. For example, we cal-
culated the survival curve for patients 
whose nursing home predictor indexes 
ranged from 1.5 to 2.5 and compared this 
curve with the curve generated by the 
algorithm for an index of 2.0. The selec-
tion of predictor index ranges for these 
analyses was guided by the distribution 
of the index scores in each case. Since our 
initial Cox analyses were stratified by age, 
these validation analyses were conducted 
separately for patients in the 2 age groups. 
We next cross-validated the algorithm 
for mortality in the sample of North 
Manhattan residents. Based on the base-
line visit data, we calculated each pa-
tient's predictor index for death. We 
then calculated a survival curve with 
95% confidence band for the patients 
and compared it with the survival curve 
associated with the median predictor in-
dex in 2 ranges of predictor values. 
RESULTS 
Mean (SD) age of the 23G patients at 
intake into the study was 73.1 (8.9) years. 
Mean estimated duration of illness was 
3.9 (2.4) years. There were 96 men and 
140 women; 84% of the group were non-
Hispanic whites. Mean mMJYIS at intake 
was 37.9 (5.6), mean BDRS was 8.0 (3.5), 
and mean CDR was 1.1 (0.8), all consis-
tent with mild disease severity. Medical 
conditions and medications at intake have 
been summarized previously.7 Of the 236 
patients, 26% were taking antihyperten-
sive medications; 9%, antidepressants; 
6%, sedative hypnotics; 3%, thyroid medi-
cation; and 6% of patients were taking 
more than 1 of these medications. Ab-
normal findings on medical evaluation 
were identified in 28%, but none of these 
was felt to contribute to the presentation 
of dementia. 
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At baseline, 26 patients (11%) had at 
least 1 extrapyramidal sign that was rated 
in the mild to moderate range and was 
not drug induced; 15 patients had extra-
pyramidal signs that were or might have 
been drug induced and were excluded 
from the analyses; and 103 patients had 
at least 1 psychotic feature. Age at onset 
was considered young ( < 65 years) in 7 4 
patients. At the time of these analyses, 
220 patients were followed up for 1 or 
more years, 199 for 2 or more years, 164 
for 3 or more years, 138 for 4 or more 
years, 94 for 5 or more years, and 43 for 
6 or more years. Maximum follow-up time 
at this point is 7 years. 
Health Related Facility Care 
Over the follow-up period, 164 patients 
were judged to have reached the point 
where they received the equivalent of 
health related facility care. Of these, 63 
were actually admitted to a nursing home 
at the same time and another 34 were 
admitted sometime later. No subject was 
admitted to a nursing home without be-
ing judged as requiring that care. Using 
t tests, we compared the scores on several 
indexes of dementia severity among pa-
tients who were and were not admitted to 
a nursing home at the point that they 
were first rated as requiring the equiva-
lent of nursing home care. The 2 groups 
did not differ significantly in level of cog-
nitive dysfunction as assessed by the 
mMMS (mean mMMS=20.3 [11.6] and 22.3 
[13.9], respectively); functional disability 
as assessed by total score on the BDRS 
(mean BDRS=15.0 [3.8] and 15.1 [5.3], re-
spectively); basic activities of daily living 
as assessed by the ED RS (meanscore=3.2 
[22] and 3.5 [3.1], respectively); and over-
all dementia severity as rated by the CD R 
(mean CDR=2.1 [0.7] and 2.2 [0.9], re-
spectively). 
Results of the Cox analysis are sum-
marized in Table 1. The relative risk (RR) 
of reaching this endpoint was significantly 
increased in patients who had extrapy-
ramidal signs or psychotic symptoms at 
their initial visit and in patients with young 
age at disease onset. Higher mMMS scores 
were associated with significantly reduced 
risk ofreaching the endpoint, and a simi-
lar trend was noted for longer estimated 
disease duration at the initial visit. The 
sex of the patient was not a significant 
predictor of nursing home level care. 
In order to check the assumptions of 
the Cox regression model, we plotted 
the martingale residuals against months 
of follow-up.24 All but 4 subjects fell 
within the predicted horizontal band 
around 0, satisfying the assumptions of 
proportional hazards. In supplementary 
analysis, we compared the Cox models 
calculated for each separately. Results 
were compatible across the 3 sites. 
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- Algorithm-Derived Survival Curve for Predictor Index of 2.0 
- Survival Curve of Patients With Predictor Index of 1.5 to 2.5 
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Figure 1.-Time to need for care equivalent to placement in health-related facil ity (HRF). comparing 
algorithm-derived survival curves with survival curves for patients aged 73 years or younger and patients 
older than 73 years at initial visit. Nearly all patient data points fall within 95% confidence bands, indicating 
that algorithms are valid models for actual patients with the given predictor index. 
Based on the 13 weights, a formula 
was developed to calculate the predic-
tor index for nursing home level care. 
The formula and its calculation are sum-
marized in Table 2. 
Table 3 summarizes the number of 
months from intake that 25%, 50%, and 
75% of subjects with a particular pre-
dictor index would be expected to re-
quire nursing home care. Note that a 
lower predictor index is associated with 
the worst prognoses, while higher val-
ues are progressively associated with 
better prognoses. 
Figure 1 displays the comparisons be-
tween the survival curves generated 
from the prediction algorithm for pre-
dictor indexes of2, 3, and 4 and survival 
curves of patients whose index at their 
initial visit was within 0.5 unit of this 
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Table 4.-Cox Proportional Hazard Analysis for 
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* RR indicates relative risk; Cl, confidence interval ; 
EPS, extrapyramidal signs; and mMMS, modified Mini-
Mental State Examination. 
value. The curves generated from the 
algorithms almost always fall within the 
95% confidence bands of the curves gen-
erated from the data. 
Mortality 
There were 99 deaths. In the Cox 
analyses there was a significantly re-
duced mortality RR for women and for 
patients with longer duration of illness. 
A similar trend was noted for patients 
with higher mMMS scores. There was a 
significantly increased mortality RR as-
sociated with the presence of extrapy-
ramidal signs (Table 4). Psychosis and 
age at onset were not significant pre-
dictors. 
To check the assumptions of the Cox 
regression model, we plotted the martin-
gale residuals against months of follow-
up.24 All subjects fell within the predicted 
horizontal band around 0, satisfying the 
assumptions of proportional hazards. In 
supplementary analysis, we compared the 
Cox models calculated for each separately. 
Results were compatible across the 3 sites. 
Based on the [3 weights, a formula 
was developed to calculate the predic-
tor index for death. The formula and its 
calculation are summarized in Table 5. 
Table 6 summarizes the number of 
months from intake that 25%, 50%, and 
75% of subjects with a particular pre-
dictor index would be expected to die. 
Again, a lower predictor index is asso-
ciated with the worst prognoses, while 
higher values are progressively associ-
ated with better prognoses. 
Figure 2 displays comparisons be-
tween the survival curves generated 
from the prediction algorithm for pre-
dictor indexes of 1 and 2 and survival 
curves of patients whose index was 
within 0.5 unit of these values at their 
initial visit. The curves generated from 
the algorithms fall well within the 95% 
confidence bands of the curves gener-
ated from the data. 
Applying the Algorithms 
To illustrate the application of the pre-
diction algorithms for nursing home care 
and death to a particular patient, we 
provide the follmving example. A 76-
year-old woman with an estimated age 
at onset of 73 years and an estimated 
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Table 5.-Guide for Calculating a Patient's Predictor Index for Death* 
Predictor Coding Value Weight Value x Weight 
Sex O Male, 1 female x 0.7046 
EPS 0 Absent, 1 present x - 1.2825 
mMMS Actual score x 0.0310 
Duration of illness Estimated years x 0.1052 
Death predictor index (sum) 
* Using the coding guidelines, a value for each predictor is entered into the "Value" column. The product of each 
predictor's value and weight is entered in the far right column. The predictor index is the sum of these products. Using 
this predictor index, estimates of the time until death can be looked up in Table 6. EPS indicates extrapyramidal signs; 
and mMMS, modified Mini-Mental State Examination. 
Table 6.-Specific Mortality Predictions for a Patient, Based on Predictor Index• 
Young (:573 y) Old (> 73 y} 
Death 
Index 25% 50% 75% 25% 50% 75% 
0 18.9 33.6 44.1 13.4 20.8 37.9 
0.2 19.0 36.4 47.3 16.2 21 .6 40.5 
0.4 21.8 40.1 54.1 16.7 23.3 44.3 
0.6 22.0 43.4 55.5 18.8 32.2 47.5 
0.8 33.5 45.2 55.7 20.8 39.9 51 .0 
1.0 35.2 50.4 58.6 21 .9 43.6 57.2 
1.2 39.3 54.9 68.6 23.3 46.3 63.1 
1.4 41 .3 55.5 71 .0 26.7 50.8 64.0 
1.6 44.5 57.8 76.7 37.9 57.0 67.1 
1.8 47.3 67.0 76.7 41.3 60.1 73.4 
2.0 54.1 69.5 77.1 44.9 63.6 74.9 
2.2 55.5 72.2 77.1 47.5 64.6 80.3 
2.4 55.7 76.7 77.5 60.0 73.4 80.3 
2.6 60.7 76.7 59.0 74.9 
2.8 68.6 77.1 63.1 80.3 
3.0 70.t 77.5 64.3 80.3 
3.2 76.7 67.t 
3.4 76.7 73.4 
3.6 77.1 74.9 
3.8 77.1 80.3 
4.0 77.5 
*For each predictor index value (as calculated in Table 5) , the table shows number of months within which the 
specified percentage of comparable patients die. Values for younger (:573 years) and older (> 73 years) patients 
are provided separately . Empty cells represent patients with milder severity at their initial v isit (and thus higher 
predictor index values) for whom there are insufficient data to generate predictions. 
3 years' duration of illness. Current 
mMMS score is 45; no extrapyramidal 
signs or psychosis is noted at the cur-
rent evaluation. Based on Table 2, the 
predictor index for nursing home care is 
3.4. Using the "Old" (age >73 years) 
column in Table 3, this patient can be 
told that 25% of similar patients require 
nursing home care within 29 months and 
50% within 49 months. Based on Table 
5, the predictor index for death is 2.4. 
Using the "Old" (age >73 years) column 
in Table 6, this patient can be told that 
25% of similar patients die within 60 
months, 50% within 73 months, and 75% 
within 80 months. 
Validation Population 
Mean age at first visit of the validation 
population was 82.5 (5.9) years. Mean es-
timated duration of illness was 3.4 (6.8) 
years. There were 15 men and 90 women. 
Mean estimated mMMS at intake was 
31.8 (4.5). At their initial visit, 30 patients 
had at least 1 extrapyramidal sign that 
was rated in the mild to moderate range 
and was not drug induced. There were 33 
deaths. 
All subjects were aged 73 years or older 
at the initial visit, so prediction of time to 
death was derived from the "Old" column 
on Table 6. Figure 3 presents the sur-
vival curve and its 95% confidence band 
for the subjects' 2 index ranges, along 
'"ith the survival curve generated from 
the predictor model for the predictor in-
dex at the median of each range. In both 
cases, the predicted survival falls well 
within the 95% confidence bands of the 
actual survival curves. 
Apolipoprotein E 
The APOE genotypes were obtained 
for 101 of the subjects from a pool of 
approximately 150 for whom they were 
potentially available. For the purpose of 
analysis, patients were dichotomized into 
2 groups, those with (n=58) and those 
without (n=43) at least 1 E4. allele. The 
stratified APOE genotype variable was 
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then introduced into the Cox models that 
were used to generate the prediction 
algorithms. 
In the Cox model, having at least 1 E4 
allele was associated with an RR of 0.69 
for reaching the nursing home care out-
come (95% confidence interval [CI], 0.38-
1.26). The RRs associated \Vith the other 
predictors remained comparable to those 
in the original model. Having at least 1 E4 
allele was associated with mortality RR 
of0.56 (95% CI, 0.27-1.6). The RRs asso-
ciated with the other predictors remained 
comparable to those in the original model. 
Postmortem Diagnosis 
Autopsies were obtained for 44 of the 
99 patients who died. Of these 44 patients, 
37 had AD, 4 had senile changes of the 
Alzheimer type (1 with concomitant pro-
gressive subcortical gliosis), 1 had diffuse 
Lewy body disease, 1 had hippocampal 
sclerosis, and 1 had a slowly progressive 
form of Creutzfeldt-Jakob disease. 
COMMENT 
Prognosis is a standard part of a medi-
cal evaluation, and it is possible to pre-
dict outcomes for many medical condi-
tions. However, these predictions have 
not been available for patients with AD. 
As with any other disease, prediction 
rests on the identification of specific dis-
ease features that impart prognostic in-
formation. We used several clinical fea-
tures that have been reliably associated 
with disease course1 and are readily as-
certainable in a clinical setting to de-
velop predictor algorithms for AD. 
The algorithms described here apply 
best to patients similar to those included 
in our study. The study was derived 
from patients seen at specialized AD 
centers, who met research criteria for 
PAD with mild to moderate disease se-
verity and were ambulatory. Patients 
with more complex medical histories and 
specific systemic illnesses may not fit 
the predictor model in the same way. 
We restricted the algorithms to the 
range of predictor indexes actually seen 
in our cohort at their initial visit. 
We validated and cross-validated the 
accw·acy of the algorithms' predictions, 
but they will benefit from further devel-
opment and validation. Replication and 
confirmation of the algorithms in other 
populations will increase accuracy. Still, 
this approach can differentiate patients 
with better and worse prognoses to a 
degree that is not currently possible. 
One encouraging feature of the cross-
validation analysis was that an estimated 
mMMS score derived from a regression 
analysis was a useful proxy for the ac-
tual score in the equation to derive the 
predictor index. We have derived equa-
tions for estimating mMMS scores from 
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Figure 2.-Time to death, comparing algorithm-derived survival curves with survival curves for patients aged 
73 years or younger and patients older than 73 years at initial visit. Nearly all patient data points fall within 
the 95% confidence bands, indicating that the algorithms are valid models for actual patients with the given 
predictor index. 
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Figure 3.-Time to death, comparing the algorithm-derived survival curve with the survival curve derived from 
an external validation population of patients with probable Alzheimer disease. All patients in the validation 
population were older than 73 years. The algorithm-derived survival curve falls with in the 95% confidence 
bands for validation population, indicating that the algorithm is valid for a new patient population. 
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other mental status scale scores includ-
ing the standard MMSE 16 (for example, 
mMMS=l.73MMSE+2.81), and this 
should broaden the applicability of the 
predictor algorithms to patients at dif-
ferent clinical centers. 
Rather than using actual entry into 
nursing home care as a study end point, 
we chose to use the point at which the 
patient began to receive the equivalent 
of this care. We chose this approach be-
cause the decision to admit a patient to 
·a nursing home is influenced by a range 
ofnonmedical factors including financial, 
cultural, and familial considerations. In 
some cases the family may elect to pro-
vide the equivalent ofnursing home level 
care in the home. The equivalent insti-
tutional care rating that we used was 
based on the entire range of instruments 
used in the semiannual evaluations, in-
cluding several measures of activities of 
daily living and a measure of patient de-
pendence.20 Patients who reached this 
end point scored comparably on a range 
of cognitive and functional measures 
whether or not they were actually placed 
in a facility. We therefore feel predicting 
this outcome is more useful for clinicians, 
patients, and their families. 
The current algorithm does not con-
sider the cause of death or the presence 
of other medical conditions that might 
contribute differentially to mortality. In 
adherence vvith NINCDS-ADRDA cri-
teria for the diagnosis of AD, patients' 
neurological examinations were notable 
only for mental status changes but were 
otherwise unremarkable, and none had 
medical conditions that would contrib-
ute to their dementia. None of the pa-
tients had a life threatening illness at 
study entry. We chose to exclude medi-
cal conditions that might arise during 
follow-up from the algorithm because 
there is no systematic way to predict 
their occurrence at the initial visit. 
Comparable to the experience in other 
clinical centers where diagnostic criteria 
are strictly applied, postmortem data sug-
gest that our diagnostic accuracy was rela-
tively high. Of the 44 autopsies performed, 
37 confirmed AD and another 4 found 
"senile changes of the Alzheimer type," 
which indicate AD-like changes that are 
out of the range of normal aging but are 
of insufficient severity or distribution to 
make the diagnosis of AD. We chose not 
to eliminate patients without confirmed 
AD from our analyses for several rea-
sons. First, we acquired autopsies for only 
half of the patients who died. It would be 
inconsistent to selectively eliminate cases 
only from the autopsied group. Second, 
all of the patients met the standard clini-
cal criteria typically used at AD research 
centers and were representative of the 
patients followed up in most AD cohorts. 
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Thus, the presented .algorithms are de-
rived from and useful for the typical pa-
tient diagnosed with AD. Since the final 
diagnosis is not available at a patient's 
initial visit, we argue that it should not 
influence the prediction algorithm. 
Patients with a longer estimated du-
ration of symptoms at their initial visit 
had a better prognosis. Thus, in 2 pa-
tients with comparable disease sever-
ity, longer duration of illness is actually 
an indicator of a more benign disease 
course. This relationship between esti-
mated duration of illness and prognosis 
has been noted in other diseases as well. 25 
Because the presence of the APOE E4 
allele is associated with earlier onset of 
AD, it is possible that disease progres-
sion might also be more rapid. However, 
reports to date have not supported this 
possibility,26 and some have suggested a 
trend toward slower disease progression 
in patients with 1 or more E4 alleles.27.28 
Our data also suggest that survival was 
better in patients with at least 1 E4 allele, 
but the RR in the current model was not 
significant. Although APOE status may 
eventually prove to have some predictive 
value for disease course, we chose to ex-
clude it from the prediction algorithms 
because the relationship between APOE 
genotype and disease progression has not 
been established, and the algorithms will 
have greater clinical utility if they rely on 
clinical signs that are readily ascertained 
at a patient visit. 
We propose these prediction algorithms 
as a first but promising step toward pro-
viding important information about the 
expected time until disease outcomes to 
patients, families, and practitioners. In 
addition to its prognostic value in a clini-
cal setting, this approach may facilitate 
design and interpretation of clinical trials 
in patients with AD by providing an ex-
pected time course to the equivalent of 
nursing home placement and death ·with 
which the patient's actual course can be 
compared. 
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